Spermosens (SPERM) Q3 2025 earnings summary

Executive summary

• Achieved key milestones, including successful clinical study of JUNO-Checked and patent approvals in Canada, Mexico, and Israel.

• Advanced development of Generation 3 JUNO-Checked, targeting faster, scalable diagnostics for male fertility.

• Engaged in active partnership discussions with potential commercial partners in Europe, the US, and other major markets.

Financial highlights

• Net sales for Q1–Q3 2025 were SEK 0 thousand, unchanged from the prior year.

• Operating loss for Q1–Q3 2025 was SEK -7,080 thousand, compared to SEK -6,790 thousand year-over-year.

• Cash and cash equivalents at period end were SEK 9,072 thousand, up from SEK 129 thousand a year earlier.

• Equity at period end was SEK 34,523 thousand, up from SEK 21,970 thousand year-over-year.

• Earnings per share for Q1–Q3 2025 was SEK 0.00, compared to SEK -0.05 for the same period last year.

Outlook and guidance

• Focus remains on securing commercial partnerships, with ambitions to enter agreements in the next year.

• Generation 3 JUNO-Checked development and validation are on track for market readiness.